Video

Dr. Kara Watts on the Society of Women in Urology at AUA 2022

Author(s):

Urology Times staff
Conference|AUA

“SWIU has just, in my humble opinion, gained incredible traction in the last few years, and it's a really great organization,” says Kara L. Watts, MD.

In this video, Kara L. Watts, MD, discusses attending the Society of Women in Urology meeting at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana. Watts is an assistant professor of urology at Montefiore Medical Center/Albert Einstein College of Medicine in Bronx, New York.

Related Videos
Related Content
Second-line cabozantinib shows efficacy in advanced renal cell carcinoma
June 9th 2025

Second-line cabozantinib shows efficacy in advanced renal cell carcinoma

Hannah Clarke
The regimen showed activity regardless of the prior immunotherapy-based combination used in the first-line setting.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC
June 5th 2025

Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC

Hannah Clarke
According to the authors, the mitomycin/BCG regimen could alleviate some of the burden of the global BCG shortage.
Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025
May 1st 2025

Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

Amy M. Pearlman, MD
Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.
Amy L. Shaver, PhD, PharmD, MPH
June 5th 2025

GLP-1 agonist use is rising in men with prostate cancer

Benjamin P. Saylor
In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
Adding niraparib to AAP extends rPFS in HRR-positive mCSPC
June 4th 2025

Adding niraparib to AAP extends rPFS in HRR-positive mCSPC

Hannah Clarke
“AMPLITUDE supports early genomic testing and niraparib plus AAP as a new treatment option for patients with mCSPC and HRR gene alterations," the authors wrote.
© 2025 MJH Life Sciences

All rights reserved.